Drug Profile

Extracorporeal hepatocyte-based therapy - Immunic

Alternative Names: ELAD; Extracorporeal bio-artificial liver; VTL C3A

Latest Information Update: 02 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Vital Therapies
Class
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Liver failure
New Molecular Entity No

Highest Development Phases

Discontinued Alcoholic hepatitis; Liver failure

Most Recent Events

12 Apr 2019 Immunic merged with Vital Therapies to form Immunic
20 Sep 2018 Discontinued - Phase-II/III for Liver failure in Saudi Arabia (Extracorporeal)
20 Sep 2018 Discontinued - Phase-III for Alcoholic hepatitis in Ireland, Germany, Spain, United Kingdom, Australia, Australia, USA (Extracorporeal)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com